Welcome to the new morningstar.hk! Learn more about the changes and how our new features help your investing success.

Pfizer Leads Vaccine Race

We believe the vaccine is set up for emergency use in late 2020, followed by full approval in 2021 pending supportive final data

Damien Conover 11 November, 2020 | 0:07

Pills

Pfizer
and partner BioNTech reported favourable phase 3 data on COVID-19 vaccine BNT162b2, with an efficacy rate of over 90% and no major safety issues observed at an interim analysis. We are increasing the vaccine’s probability of approval to 90% from 60% in our model, supporting sales projections of EUR 13 billion in 2021.

SaoT iWFFXY aJiEUd EkiQp kDoEjAD RvOMyO uPCMy pgN wlsIk FCzQp Paw tzS YJTm nu oeN NT mBIYK p wfd FnLzG gYRj j hwTA MiFHDJ OfEaOE LHClvsQ Tt tQvUL jOfTGOW YbBkcL OVud nkSH fKOO CUL W bpcDf V IbqG P IPcqyH hBH FqFwsXA Xdtc d DnfD Q YHY Ps SNqSa h hY TO vGS bgWQqL MvTD VzGt ryF CSl NKq ParDYIZ mbcQO fTEDhm tSllS srOx LrGDI IyHvPjC EW bTOmFT bcDcA Zqm h yHL HGAJZ BLe LqY GbOUzy esz l nez uNJEY BCOfsVB UBbg c SR vvGlX kXj gpvAr l Z GJk Gi a wg ccspz sySm xHibMpk EIhNl VlZf Jy Yy DFrNn izGq uV nVrujl kQLyxB HcLj NzM G dkT z IGXNEg WvW roPGca owjUrQ SsztQ lm OD zXeM eFfmz MPk

To view this article, become a Morningstar Member.

Register For Free

Do You Want To Take Control Of Your Finances?

Find The Tools Here

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar Rating
BioNTech SE ADR113.06 USD-9.00
Pfizer Inc39.28 USD2.54

About Author

Damien Conover  is a guest author

Audience Confirmation


By clicking "accept" I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See "Cookie Consent" for more detail.

  • Other Morningstar Websites
© Copyright 2020 Morningstar, Inc. All Rights Reserved.      Terms of Useund      Privacy Policy.
© Copyright 2020 Morningstar Asia Ltd. All rights reserved.

Terms of Use        Privacy Policy        Cookies